Alnylam identifies who's getting ax

Alnylam Pharmaceuticals ($ALNY) has detailed plans for laying off 52 workers, part of a broad effort to slash its RNA workforce 33%. The Boston Business Journal reports that the biotech told state officials it is axing its senior director of biotherapeutics, a senior director of business development, a senior director of pharma operations and a senior director of information technology. The Journal reports that "nine senior scientists and 14 research associates positions will also be eliminated." Story

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.